The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understanding how different types of weight loss treatment impact pelvic floor symptoms will help clinicians guide which weight loss treatments are recommended for patients with pelvic floor symptoms in the future.
female
18-89 years old
any race/ethnicity
BMI ≥30 kg/m2
Pregnant
≥90 years old
<18 years old
BMI <30 kg/m2
Patients seeking medical weight loss or surgical weight loss at the weight loss clinics at Hartford Hospital.
Case-control
Cross-sectional
Bariatric Surgery
Procedure/SurgeryPatients in this arm plan to undergo gastric sleeve or gastric bypass surgery.
GLP1 receptor agonist
DrugPatients in this arm plan to start a GLP-1 receptor agonist.
Change in pelvic floor symptoms measured by survey the Urogenital Distress Inventory (UDI)
The investigators plan to measure the change in pelvic floor symptoms between woman taking glucagon-like peptide-1 receptor agonists (GLP1) medications vs women receiving bariatric surgery. These changes will be measured by validated survey, including the Urogenital Distress Inventory (UDI)
Change in pelvic floor symptoms measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8).
The investigators plan to measure the change in pelvic floor symptoms between woman taking glucagon-like peptide-1 receptor agonists (GLP1) medications vs women receiving bariatric surgery. These changes will be measured by validated survey the Colorectal-Anal Distress Inventory (CRADI-8).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
